Saniona: Major SAN2355 deal with Jazz Pharmaceuticals - Redeye

Redeye comments on the positive news that Saniona has outlicensed SAN2355 to Jazz Pharmaceuticals in epilepsy and other potential indications, with a total deal value of USD1.035bn + royalties, including an upfront of USD42.5m. We see this as yet another major breakthrough that should open possibilities for the company to advance and broaden its internal pipeline. Furthermore, we believe the market is not fully valuing today’s announcement.

Länk till analysen i sin helhet: https://www.redeye.se/research/1123547/saniona-major-san2355-deal-with-jazz?utm_source=finwire&utm_medium=RSS